A.R.T. Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

A.R.T. Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,210	Closed	-$66K	–	288
2019 Q4	$66K	Buy	+1,210	New	+$113K	﹤0.01%	1239

Other funds holding CYCN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

A.R.T. Advisors's CYCN Position: Q1 2020 in Review

A.R.T. Advisors sold out of Cyclerion Therapeutics (CYCN) in Q1 2020, closing a stake of 1,210 shares — an estimated $66K sold.

A.R.T. Advisors first reported a position in CYCN in Q4 2019 and held it in 1 quarter. The position peaked at $66K in Q4 2019. 80 funds tracked by Wall St. Rank hold CYCN as of Q1 2020.

A.R.T. Advisors reported no remaining Cyclerion Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 1,210 Cyclerion Therapeutics shares in Q1 2020, an estimated $66K.
A.R.T. Advisors first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 1 quarter.
A.R.T. Advisors's Cyclerion Therapeutics position peaked at $66K in Q4 2019.
80 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.